What FLT3‑TKD–directed maintenance regimen should be used after allogeneic hematopoietic stem cell transplantation in a patient with a FLT3 tyrosine‑kinase‑domain mutation and a KMT2A‑ELL fusion who achieved first complete remission with measurable residual disease 0.02% before transplant and has measurable residual disease 0% at 90 days post‑transplant?

FLT3-TKD Post-Transplant Maintenance Recommendation

Despite your FLT3-TKD mutation (not FLT3-ITD) and achievement of MRD negativity at day 90 post-transplant, you should still initiate FLT3 inhibitor maintenance therapy with sorafenib 400 mg daily (200 mg twice daily) for a minimum of 2 years, provided you have adequate hematologic reconstitution and no active acute GVHD.

Critical Context: FLT3-TKD vs FLT3-ITD

The available guidelines specifically address FLT3-ITD mutations, not FLT3-TKD (tyrosine kinase domain) mutations. This is a crucial distinction because:

• FLT3-ITD represents 25-30% of FLT3-mutated AML and has robust evidence for post-transplant maintenance 1
• FLT3-TKD mutations have different biology and generally better prognosis than FLT3-ITD
• The EBMT guidelines explicitly state that "post-transplant maintenance with FLT3 inhibitors outside FLT3-ITD AML" remains an unresolved question 1

Rationale for Proceeding with Maintenance Despite FLT3-TKD

Why Maintenance is Still Recommended:

1. Extrapolation from FLT3-ITD Evidence

• Post-transplant FLT3 inhibitor maintenance significantly improves outcomes in FLT3-ITD patients, with OS improvement (HR 0.41,95% CI 0.32-0.52) and reduced relapse risk (HR 0.31,95% CI 0.20-0.46) 2
• Real-world German registry data showed 5-year OS of 85% with sorafenib maintenance versus 62% without (HR 2.979, p=0.0045) 3

2. Your Specific Risk Profile

• You had MRD 0.02% before transplant, indicating residual disease burden
• While you achieved MRD 0% at day 90, the EBMT guidelines emphasize that maintenance should be initiated "especially in patients with MRD-positive AML before or after allo-SCT" 1
• Your pre-transplant MRD positivity places you in a higher-risk category despite current MRD negativity

3. KMT2A-ELL Fusion Consideration

• KMT2A (formerly MLL) rearrangements confer adverse prognosis
• The combination of FLT3 mutation with KMT2A rearrangement represents high-risk disease biology
• This further supports aggressive post-transplant strategies

Specific Maintenance Protocol

Dosing Strategy:

Standard Dose (Recommended for Your Case):

• Sorafenib 400 mg/day (200 mg twice daily) 1
• Since you achieved MRD negativity post-transplant, the standard dose is appropriate

Alternative Higher Dose:

• 800 mg/day (400 mg twice daily) is reserved for patients with persistent MRD-positive disease 1
• Not indicated in your case given MRD 0% at day 90

Timing:

• Initiate "as soon as possible after disease evaluation, including MRD assessment" 1
• Requires adequate hematologic reconstitution
• Typically started between day 30-120 post-transplant 3

Duration:

• Minimum 2 years recommended 1
• Adjust based on tolerance
• Some patients continue longer depending on risk factors and tolerance

Management Considerations

When to Hold Sorafenib:

• Active acute GVHD requiring systemic corticosteroids - temporarily discontinue 1
• May cautiously resume once GVHD remission documented
• Chronic GVHD is not an absolute contraindication

Monitoring Requirements:

• Drug-drug interactions (particularly with calcineurin inhibitors) 1
• Cytopenias requiring dose adjustments 4
• Skin toxicity (increased risk: RR 5.86) 2
• Long-term side effects 1

Common Pitfalls:

1. Delaying initiation - Start promptly after MRD assessment and hematologic recovery
2. Premature discontinuation - Maintain for full 2 years unless toxicity prohibits
3. Inadequate dose adjustments - Balance efficacy with tolerability
4. Missing drug interactions - Careful monitoring with immunosuppression

Alternative FLT3 Inhibitors

While sorafenib is the preferred option based on available evidence 1, other agents are under investigation:

• Gilteritinib: Showed benefit in MRD-positive patients in recent trials 4, but limited data for FLT3-TKD specifically
• Midostaurin: Used in 37% of maintenance cases in real-world data 3, but less robust evidence than sorafenib
• Quizartinib: Approved for maintenance in some regions, but primarily studied in FLT3-ITD 5

Sorafenib remains the evidence-based first choice given its extensive study in the post-transplant setting 1.

Evidence Limitations

Critical caveat: All guideline recommendations are Grade B-II or B-III evidence 1, reflecting:

• Limited randomized controlled trial data
• Predominantly observational studies
• Specific focus on FLT3-ITD, not FLT3-TKD

The 2025 EBMT guidelines acknowledge that "post-transplant maintenance with FLT3 inhibitors outside FLT3-ITD AML" requires further investigation 4, but given your pre-transplant MRD positivity and high-risk genetics (KMT2A-ELL), the benefit-risk ratio favors proceeding with maintenance therapy.

Practical Implementation

1. Confirm adequate counts before starting (typically ANC >1000, platelets >50,000)
2. Start sorafenib 200 mg twice daily with food
3. Monitor CBC weekly for first month, then monthly
4. Check drug levels of immunosuppression if still on calcineurin inhibitors
5. Continue for minimum 2 years unless prohibitive toxicity
6. Serial MRD monitoring every 3 months to assess response

1, 4, 3